BioCryst Pharmaceuticals BCRX Lessee Operating Lease Liability Undiscounted Excess Amount
Lessee Operating Lease Liability Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's lessee operating lease liability undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's lessee operating lease liability undiscounted excess amount?
- BioCryst Pharmaceuticals (BCRX) reported lessee operating lease liability undiscounted excess amount of $5.98M in Q1 2026.
- How has BioCryst Pharmaceuticals's lessee operating lease liability undiscounted excess amount changed year-over-year?
- BioCryst Pharmaceuticals's lessee operating lease liability undiscounted excess amount increased by 9.3% year-over-year, from $5.47M to $5.98M.